JP2023538236A5 - - Google Patents
Info
- Publication number
- JP2023538236A5 JP2023538236A5 JP2023504727A JP2023504727A JP2023538236A5 JP 2023538236 A5 JP2023538236 A5 JP 2023538236A5 JP 2023504727 A JP2023504727 A JP 2023504727A JP 2023504727 A JP2023504727 A JP 2023504727A JP 2023538236 A5 JP2023538236 A5 JP 2023538236A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- composition
- liver disease
- peptide
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2020-0102604 | 2020-08-14 | ||
| KR20200102604 | 2020-08-14 | ||
| KR20210048006 | 2021-04-13 | ||
| KR10-2021-0048006 | 2021-04-13 | ||
| PCT/KR2021/010910 WO2022035302A1 (ko) | 2020-08-14 | 2021-08-17 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 혈압 강하용 약학 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023538236A JP2023538236A (ja) | 2023-09-07 |
| JP2023538236A5 true JP2023538236A5 (https=) | 2024-08-27 |
Family
ID=80247176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023504727A Pending JP2023538236A (ja) | 2020-08-14 | 2021-08-17 | グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体を含む血圧降下用薬学組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240024426A1 (https=) |
| EP (1) | EP4197550A4 (https=) |
| JP (1) | JP2023538236A (https=) |
| KR (1) | KR20220021895A (https=) |
| CN (1) | CN116322786A (https=) |
| AU (1) | AU2021326369A1 (https=) |
| CA (1) | CA3188884A1 (https=) |
| IL (1) | IL300017A (https=) |
| MX (1) | MX2023001601A (https=) |
| WO (1) | WO2022035302A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4197560A4 (en) * | 2020-08-14 | 2025-11-26 | Hanmi Pharmaceutical Co Ltd | Pharmaceutical composition comprising a persistent triple activator conjugate used as the active ingredient. |
| JP2023543036A (ja) * | 2020-09-25 | 2023-10-12 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体またはその結合体の神経退行性疾患の治療用途 |
| WO2022080987A1 (ko) * | 2020-10-16 | 2022-04-21 | 한미약품 주식회사 | 글루카곤/glp-1/gip 삼중작용제 또는 이의 지속형 결합체를 포함하는 혈관염 예방 또는 치료용 약학적 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| CN105829339B (zh) * | 2013-11-06 | 2021-03-12 | 西兰制药公司 | 胰高血糖素-glp-1-gip三重激动剂化合物 |
| JP6280398B2 (ja) * | 2014-03-04 | 2018-02-14 | 株式会社ナガセビューティケァ | Ｇｌｐ−１分泌促進剤 |
| TWI802396B (zh) * | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| EP4523705A3 (en) * | 2015-06-30 | 2025-06-11 | Hanmi Pharm. Co., Ltd. | Glucagon derivative and a composition comprising a long acting conjugate of the same |
| EP3384935A4 (en) * | 2015-12-02 | 2019-08-21 | Hanmi Pharm. Co., Ltd. | PROTEIN COMPLEX WITH FATTY ACID DERIVATIVE AND MANUFACTURING METHOD THEREFOR |
| SG11201805586SA (en) | 2015-12-31 | 2018-07-30 | Hanmi Pharmaceutical Co Ltd | Triple glucagon/glp-1/gip receptor agonist |
| AR110300A1 (es) * | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip |
| EP4197560A4 (en) * | 2020-08-14 | 2025-11-26 | Hanmi Pharmaceutical Co Ltd | Pharmaceutical composition comprising a persistent triple activator conjugate used as the active ingredient. |
-
2021
- 2021-08-17 EP EP21856308.8A patent/EP4197550A4/en active Pending
- 2021-08-17 US US18/041,151 patent/US20240024426A1/en active Pending
- 2021-08-17 IL IL300017A patent/IL300017A/en unknown
- 2021-08-17 MX MX2023001601A patent/MX2023001601A/es unknown
- 2021-08-17 KR KR1020210108368A patent/KR20220021895A/ko active Pending
- 2021-08-17 CA CA3188884A patent/CA3188884A1/en active Pending
- 2021-08-17 JP JP2023504727A patent/JP2023538236A/ja active Pending
- 2021-08-17 AU AU2021326369A patent/AU2021326369A1/en active Pending
- 2021-08-17 CN CN202180063776.6A patent/CN116322786A/zh active Pending
- 2021-08-17 WO PCT/KR2021/010910 patent/WO2022035302A1/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023538236A5 (https=) | ||
| JP2017533194A5 (https=) | ||
| CN102917726B (zh) | 干扰素类似物 | |
| RU2017112738A (ru) | Фармацевтические композиции, содержащие варианты пептидов, и способы их применения | |
| JP2025137626A5 (https=) | ||
| JP2021508449A5 (https=) | ||
| JP2023504914A5 (https=) | ||
| JP2019524675A5 (https=) | ||
| JP2022518210A5 (https=) | ||
| JP2008507298A5 (https=) | ||
| JP2013545724A5 (https=) | ||
| JP2022504153A5 (https=) | ||
| JP2023502005A5 (https=) | ||
| IL300017A (en) | A hypotensive pharmaceutical composition that includes a triple activator with activity against all glucagon, GLP-1 and GIP receptors | |
| CA2778890A1 (en) | Glycosylated form of antigenic glp-1 analogue | |
| JP2025504625A5 (https=) | ||
| JP2012531219A5 (https=) | ||
| CN117794946A (zh) | 长效双重gip/glp-1肽缀合物及使用方法 | |
| JP2024527613A5 (https=) | ||
| FI3936142T3 (fi) | Kaikkien glukagoni-, glp-1- ja gip-reseptorien suhteen aktiivisuutta omaava kolmoisagonisti maksasairauden hoitoon | |
| JP2023549854A5 (https=) | ||
| JP2024500605A5 (https=) | ||
| CN114829377A (zh) | 用于预防和/或治疗hbv和/或hdv感染、肝脏疾病和用于靶向ntcp的偶联化合物 | |
| CN114685646A (zh) | 一种多肽侧链类似物的制备方法及其应用 | |
| IL299778A (en) | Therapeutic use of glucagon derivative or conjugate thereof for liver disease |